Global Dashboard on COVID-19 Vaccine Equity

Posted on by

Milestones :: Perspectives :: Research

 

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 25 Sep 2021]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability

Coronavirus (COVID-19) Vaccinations [Accessed 25 Sep 2021]

Posted on by

Milestones :: Perspectives :: Research

 

Our World in Data
Coronavirus (COVID-19) Vaccinations [Accessed 25 Sep 2021]
:: 44.3% of the world population has received at least one dose of a COVID-19 vaccine.
:: 6.1 billion doses have been administered globally, and 29.41 million are now administered each day.
:: Only 2.2% of people in low-income countries have received at least one dose.

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Posted on by

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

CDC [ACIP]

CDC Statement on ACIP Booster Recommendations

Friday, September 24, 2021

Today, CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation for a booster shot of the Pfizer-BioNTech COVID-19 vaccine in certain populations and also recommended a booster dose for those in high risk occupational and institutional settings. The Food and Drug Administration’s (FDA) authorization and CDC’s guidance for use are important steps forward as we work to stay ahead of the virus and keep Americans safe.

This updated interim guidance from CDC allows for millions of Americans who are at highest risk for COVID-19 to receive a Pfizer-BioNTech COVID-19 booster shot to help increase their protection.

CDC recommends:

  • people 65 years and older and residents in long-term care settings should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series,
  • people aged 50–64 years with underlying medical conditionsshould receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series,
  • people aged 18–49 years with underlying medical conditionsmay receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks, and
  • people aged 18-64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks.

Many of the people who are now eligible to receive a booster shot received their initial vaccine early in the vaccination program and will benefit from additional protection. With the Delta variant’s dominance as the circulating strain and cases of COVID-19 increasing significantly across the United States, a booster shot will help strengthen protection against severe disease in those populations who are at high-risk for exposure to COVID-19 or the complications from severe disease.

CDC will continue to monitor the safety and effectiveness of COVID-19 vaccines to ensure appropriate recommendations to keep all Americans safe. We will also evaluate with similar urgency available data in the coming weeks to swiftly make additional recommendations for other populations or people who got the Moderna or Johnson & Johnson vaccines.

The following is attributable to Dr. Walensky:

As CDC Director, it is my job to recognize where our actions can have the greatest impact. At CDC, we are tasked with analyzing complex, often imperfect data to make concrete recommendations that optimize health. In a pandemic, even with uncertainty, we must take actions that we anticipate will do the greatest good.

I believe we can best serve the nation’s public health needs by providing booster doses for the elderly, those in long-term care facilities, people with underlying medical conditions, and for adults at high risk of disease from occupational and institutional exposures to COVID-19. This aligns with the FDA’s booster authorization and makes these groups eligible for a booster shot. Today, ACIP only reviewed data for the Pfizer-BioNTech vaccine. We will address, with the same sense of urgency, recommendations for the Moderna and J&J vaccines as soon as those data are available.

While today’s action was an initial step related to booster shots, it will not distract from our most important focus of primary vaccination in the United States and around the world. I want to thank ACIP for their thoughtful discussion and scientific deliberation on the current data which informed my recommendation.

::::::

 

Changes in booster shot guidance lead to confusion for doctors, patients

Washington Post, 9/25/2021

The muddle came to a head with this week’s showdown between the CDC’s advisers and its director. Health care providers are now trying to get answers to patients’ questions — and their own.

By Carissa Wolf, Frances Stead Sellers, Ashley Cusick and Kim Mueller

…Confusion over boosters, which has been brewing for months, heightened over the past week as government regulators and advisers met to hash out the pros and cons of administering third doses.

Hours of meetings culminated in a showdown Thursday: The Centers for Disease Control and Prevention’s advisory group narrowed the Food and Drug Administration’s recommendation for who should get a third Pfizer shot, only to be overruled in a late-night announcement by the CDC director: Along with Americans 65 and older, nursing home residents and people ages 50 to 64 with underlying medical conditions, who the advisory panel had suggested should get shots, Rochelle Walensky added the people in high-risk jobs.

“It’s a communications crisis,” said Robert Murphy, executive director of the Institute for Global Health at Northwestern University Feinberg School of Medicine, who said he received worried calls Thursday evening from health-care workers who thought they would not be eligible for the shots, followed by messages Friday from colleagues wondering when and where to get them…

::::::

Vaccines and Related Biological Products Advisory Committee- FDA

 

Vaccines and Related Biological Products Advisory Committee September 30, 2021 Meeting Announcement

Agenda
Under Topic I, the committee will meet in open session to hear an overview of the research programs in the Laboratory of Bacterial Polysaccharides (LBP), Division of Bacterial, Parasitic, and Allergenic Products (DBPAP), Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER).

Also, on September 30, 2021, under Topic II, the Center for Biologics Evaluation and Research’s (CBER) VRBPAC will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2021 to 2022 southern hemisphere influenza season.

YouTube recording: https://youtu.be/VeknygU5MKM

::::::

White House [U.S.]
Briefing Room – Selected Major COVID Announcements
Press Briefing by White House COVID-⁠19 Response Team and Public Health Officials
September 24, 2021 • Press Briefings

Global COVID-⁠19 Summit: Ending the Pandemic and Building Back Better
September 24, 2021 • Statements and Releases
Editor’s Note:
This statement provides the U.S. narrative on the “Virtual Global COVID-19 Summit” as further detailed by the speeches, statement and releases below. It includes quotations attributable to and a list of “more than 100 governments and other partners” which participated and the “more than 100 International Organizations, non-governmental organizations, private sector, and philanthropies” which participated. We recognize the limited alignment between this statement and the tone and detail of the COVAX partners announcement on the Biden Summit above.

Remarks by President Biden on the COVID-⁠19 Response and the Vaccination Program
September 24, 2021 • Speeches and Remarks

Remarks by Vice President Harris At Virtual Global COVID-⁠19 Summit
September 22, 2021 • Speeches and Remarks

Remarks by President Biden at Virtual Global COVID-⁠19 Summit
September 22, 2021 • Speeches and Remarks

A U.S.-EU Agenda for Beating the Global Pandemic Vaccinating the World, Saving Lives Now, and Building Back Better Health Security
September 22, 2021 • Statements and Releases

United States–European Commission Joint Statement
September 22, 2021 • Statements and Releases
Editor’s Note:
This statement provides details on the launch of the joint COVID-19 Manufacturing and Supply Chain Taskforce first announced in June. This week, the Taskforce met in Washington, D.C., to finalize the Mission Statement of this Taskforce, which will focus on the following three priority “work strands” including: [1] Monitor global supply chains for COVID-19 vaccines and therapeutics through assessment of global demand and supply of these items and their production and ancillary supplies, and through identification of supply chain bottlenecks; [2] Address critical supply chain bottlenecks and other disruptive factors for global COVID-19 vaccine and therapeutics production, and [3] Coordinate initiatives to boost global production of COVID-19 vaccines, therapeutics, and their production and ancillary supplies.

FACT SHEET: President Biden’s Global COVID-⁠19 Summit: Ending the Pandemic and Building Back Better
September 22, 2021 • Statements and Releases

FACT SHEET: Targets for Global COVID-⁠19 Summit
September 22, 2021 • Statements and Releases
[See Milestones above for detail]

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Posted on by

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

 

European Medicines Agency
News & Press Releases
No new digest content identified

 

 

::::::

 

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
Latest Updates
Publication
Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA
Technical report – 23 Sep 2021
This report provides an updated overview of the progress of national COVID-19 vaccination strategies in EU/EEA countries, including updates on: vaccine uptake overall and by target group; current vaccination phases and priority groups, as well as any adjustments made to priority groups during the rollout; vaccination strategies and policies in place; and the use of vaccination certificates and challenges countries face with the rollout and good practices to mitigate these challenges.

Publication
Protocol for a focused after-action review on evidence-based decision-making for selected COVID-19 response measures
Technical report – 22 Sep 2021
This ECDC protocol for a focused after-action review (AAR) on evidence-based decision-making (EBDM) for selected COVID-19 response measures uses the standard AAR/IAR approach but focuses on a single category or function – EBDM – as opposed to a whole range of activities. We consider the decision (or group of decisions) made as the event to be reviewed, whereby the event comprises both the process that leads to the decision outcome and the impact of that outcome. It follows a case study-based research design. In the social sciences, a case study approach looks at one selected event in depth and explores what can be learned about broader, systemic interrelationships and linkages. Due to the complex impact of COVID-19 on all aspects of society, an investigation of the intricacies of EBDM demands a focused approach.

 

 

::::::

Data as of 2021-09-24
https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab

 

 

::::::

 

European Commission
https://ec.europa.eu/commission/presscorner/home/en
Press release 17 September 2021
Statement 25 September 2021
Statement by President von der Leyen at the Global Citizen live event ‘A Recovery Plan for the World’

Press release 23 September 2021
Europeans strongly support science and technology according to new Eurobarometer survey
A new Eurobarometer survey on ‘European citizens’ knowledge and attitudes towards science and technology’ released today shows that 9 in 10 EU citizens (86%) think that the overall influence of science and technology is positive.

Statement 22 September 2021
United States–European Commission Joint Statement: Launch of the joint COVID-19 Manufacturing and Supply Chain Taskforce

Statement 22 September 2021
An U.S.-EU Agenda for Beating the Global Pandemic: Vaccinating the World, Saving Lives Now, and Building Back Better Health Security

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Posted on by

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

 

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

Latest Updates
No new digest content identified

 

 

Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified

 

 

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified

POLIOPublic Health Emergency of International Concern (PHEIC)

Posted on by

Emergencies

POLIO
Public Health Emergency of International Concern (PHEIC)
https://polioeradication.org/polio-today/polio-now/this-week/

Polio this week as of 23 September 2021
:: “Afghanistan is one of two countries in the world where polio remains endemic. With only one case of wild poliovirus reported so far this year, compared to 56 in 2020, there has never been a better time to eradicate polio. However, the polio programme will struggle to respond if the basic immunization infrastructure begins to collapse around it.” – Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, and Dr Ahmed Al-Mandhari, WHO Regional Director for the Eastern Mediterranean on their visit to Kabul. Read more…

 

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):
No new WPV and cVDPV cases reported this week

 

::::::

Event – Eradicating Polio: What more Is Needed?
WFPHA – World Federation of Public Health Associations
Sep 22, 2021
Polio cases have fallen 99.9% since 1988. In 2020 Africa was certified polio free by the World Health Organization. However, polio will remain a key public health concern until such time as there are no wild… On October 12, 2021, at 10:00 – 11:00 (CEST), “Eradicating Polio: What more Is Needed?” webinar will be held to focus on the barriers, challenges and leverages to reach every child and eradicate polio globally. Register

 

::::::
::::::

WHO/OCHA Emergencies

 

Editor’s Note:
WHO has apparently reorganized and fundamentally shifted how it judges and tracks “emergencies”. We found no announcement of descriptive information to share and present the webpage structure as encountered below. Obviously, the dates associated with some of these emergencies suggest that this is an archival platform as well as a current emergencies resource.

Health emergencies list – WHO
“The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences.”

Crisis in Tigray, Ethiopia [Last apparent update: 5 Aug 2021]

Ebola outbreak, Democratic Republic of the Congo, 2021 [Last apparent update: 17 Aug 2021]

Ebola outbreak outbreak, N’Zerekore, Guinea, 2021 [Last apparent update: 17 Aug 2021]

Coronavirus disease (COVID-19) pandemic [See COVID above]

 

Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020
[Last apparent update: 17 Aug 2021]

Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020
[Last apparent update: 17 Aug 2021]

Ebola outbreak, Democratic Republic of the Congo, 2018 [Last apparent update: 24 July 2018]

Yemen crisis [Last apparent update: 12 February 2021]

Syria crisis [Last apparent update: 18 June 2021]

Somalia crisis [Last apparent update: 24 March 2018]

Nigeria crisis [Last apparent update: 9 May 2018]

Ebola outbreak, Democratic Republic of the Congo, 2017 [Last apparent update: 17 Aug 2021]

Zika virus disease outbreak, 2015-2016 [Last apparent update: 24 Jan 2020]

Ebola outbreak: West Africa, 2014-2016 [Last apparent update: 17 Aug 2021]

Iraq crisis [Last apparent update: 9 Jan 2008]

South Sudan crisis [Last apparent update: 23 Sep 2020]

Avian influenza A (H7N9) virus outbreak [Last apparent update: 13 September 2021]

Middle East respiratory syndrome (MERS-CoV) outbreak [Last apparent update: 8 July 2019]

Influenza A (H1N1) virus, 2009-2010 pandemic [Last apparent update: 10 Aug 2010]

 

::::::

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
Afghanistan: Humanitarian Snapshot (As of 24 September 2021)
OVERVIEW
Forty years of war, recurrent natural disasters, chronic poverty, drought and the COVID-19 pandemic have devastated the people of Afghanistan. The recent escalation in conflict and resulting upheaval has only exacerbated needs and further complicated an extremely challenging operational context. Even prior to the events of 15 August, the humanitarian situation in Afghanistan was one of the worst in the world. By the mid-year mark, nearly half of the population — some 18.4m people — were already in need of humanitarian and protection assistance in 2021.

Northern Ethiopia
Ethiopia – Northern Ethiopia Humanitarian Update Situation Report, 23 Sept 2021

 

::::::
::::::

CDC/ACIP [U.S.] [to 25 Sep 2021]

Posted on by

CDC/ACIP [U.S.] [to 25 Sep 2021]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases, Announcements
Studies Show More COVID-19 Cases in Areas Without School Masking Policies
Friday, September 24, 2021

CDC Statement on ACIP Booster Recommendations
Friday, September 24, 2021
[See US regulatiory action ab

Next ACIP Meetings
No registration is required to watch the webcast.
:: September 29, 2021, 10:00 a.m. – 5:30 p.m. virtual meeting at https://video.ibm.com/channel/VWBXKBR8af4
Agenda draft: https://www.cdc.gov/vaccines/acip/meetings/downloads/agenda-archive/Draft_Meeting-Agenda_Sept-29-2021_for-posting-508.pdf

MMWR News Synopsis Friday, September 24, 2021
Selected Content
:: Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021
:: Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021
:: Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison — Texas, July–August 2021

Coronavirus Disease 2019 (COVID-19)– CDC
Approximately 25 announcements/reports/data summaries.
:: Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 24 Sep 2021 06:00:00 EST

China CDC http://www.chinacdc.cn/en/

Posted on by

China CDC http://www.chinacdc.cn/en/

National Health Commission of the People’s Republic of China [to 25 Sep 2021]
http://en.nhc.gov.cn/
News
Sept 25: Daily briefing on novel coronavirus cases in China
On Sept 24, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 38 new cases of confirmed infections

Xi stresses beating COVID-19
Updated: 2021-09-22 | Xinhua
BEIJING — Chinese President Xi Jinping said on Sept 21 that we must beat COVID-19 and win this decisive fight crucial to the future of humanity.
Xi made the remarks in his statement delivered via video at the general debate of the 76th session of the United Nations General Assembly.
“The history of world civilization is also one of fighting pandemics. Rising to challenges, humanity has always emerged in triumph and achieved greater development and advancement. The current pandemic may appear overwhelming, but we humanity will surely overcome it and prevail,” said Xi.

National Medical Products Administration – PRC [to 25 Sep 2021]
http://english.nmpa.gov.cn/news.html
News
Nearly 2.19b COVID-19 vaccine doses administered in China
2021-09-24
Nearly 2.19 billion COVID-19 vaccine doses had been administered in China as of Sept 22, data from the National Health Commission showed Sept 23.

China to provide more vaccines, international assistance
2021-09-22
Chinese President Xi Jinping said Tuesday that China will provide more vaccines against COVID-19 to the world, as well as international assistance.

CCDC Weekly – Weekly Reports: Current Volume (3)
2021-09-24 / No. 39
View  PDF of this issue
:: Foreword: Accelerate the Progress Towards Elimination of Dog-Mediated Rabies in China
:: Vital Surveillances: Epidemiology of Animal Rabies — China, 2010–2020
:: Vital Surveillances: Epidemic Characteristics of Human Rabies — China, 2016–2020
:: Preplanned Studies: Epidemiological Study of Outpatients in Rabies Post-Exposure Prophylaxis Clinics — Tianjin Municipality, China, 2020
:: Commentary: Progress in the Development of Animal Rabies Vaccines in China
:: Commentary: Progress and Prospects of Dog-Mediated Rabies Elimination in China

Organization Announcements

Posted on by

::::::

 

Organization Announcements
Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 25 Sep 2021]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
News
No new digest content identified.

BARDA – U.S. Department of HHS [to 25 Sep 2021]
https://www.phe.gov/about/barda/Pages/default.aspx
News
No new digest content identified.

BMGF – Gates Foundation [to 25 Sep 2021]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
Press release
Sep 23, 2021
The Bill & Melinda Gates Foundation Commits $922 Million to Advance Global Nutrition to Help Women and Children

Press release
Sep 20, 2021
Bill & Melinda Gates Foundation Honors Phumzile Mlambo-Ngcuka, Former Executive Director of UN Women, With 2021 Global Goalkeeper Award

Bill & Melinda Gates Medical Research Institute [to 25 Sep 2021]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X [to 25 Sep 2021]
https://carb-x.org/
News
07.29.2021  |
CARB-X celebrates five years of progress in early-stage product development against antibiotic-resistant bacteria
CARB-X, a global non-profit partnership led by Boston University, is celebrating five years of progress in funding and supporting the development of innovative products targeting antibiotic-resistant bacteria. Since it was founded in July 2016, CARB-X has invested $361 million in non-dilutive funding to develop innovative therapeutics including new classes of antibiotics and non-traditional agents, vaccines and other preventatives such as CRISPR-phage, microbiome-modifying agents and antibodies, and rapid diagnostics.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 25 Sep 2021]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions and posting of all segments of Vaccines and Global Health: The Week in Review are available here.
:: [NEW] Informed Consent: A Monthly Review – September 2021 is now posted here

CEPI – Coalition for Epidemic Preparedness Innovations [to 25 Sep 2021]
http://cepi.net/
Latest News
Global leaders commit further support for global equitable access to COVID-19 vaccines and COVAX
Joint statement from COVAX following the Global COVID-19 Summit hosted by the United States
COVAX
23 Sep 2021
[See Milestones above for detail]

Clover Biopharmaceuticals announces positive efficacy data from Phase 2/3 trial
SCB-2019 (CpG 1018/Alum) demonstrated significant efficacy against multiple variants of COVID-19, including Delta
COVID-19
22 Sep 2021

DARPA – Defense Advanced Research Projects Agency [to 25 Sep 2021
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center [to 25 Sep 2021]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP [to 25 Sep 2021]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
No new digest content identified.

Emory Vaccine Center [to 25 Sep 2021]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 25 Sep 2021]
http://www.euvaccine.eu/
Latest News
No new digest content identified.

Fondation Merieux [to 25 Sep 2021]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

Gavi [to 25 Sep 2021]
https://www.gavi.org/
23 September 2021
Global leaders commit further support for global equitable access to COVID-19 vaccines and COVAX
[See Milestones above for detail]

22 September 2021
DFC and Citi Risk Management Solution Helps Gavi Strengthen the Foundations of the COVAX Facility
:: DFC financing for vaccine-related efforts now totals nearly $600m committed during the Biden Administration
:: U.S. International Development Finance Corporation, in conjunction with Citi, launch risk management solution for COVAX Facility
:: Helps to insure against risk in 9 self-financing countries participating in COVAX
:: COVAX aims to provide fair and equitable access to COVID-19 vaccines for every country in the world
Washington, New York and Geneva, 22 September 2021 – U.S. International Development Finance Corporation (DFC), in conjunction with Citi, today announced it is providing a risk management solution to Gavi, the Vaccine Alliance (Gavi), to mitigate risk and overcome financial hurdles with governments that are funding COVID-19 vaccine purchases through the COVAX Facility. One of many actions unveiled at the U.S. COVID-19 Summit and highlighted by the White House, this risk management partnership embodies the collective and global action that will be required to address and end the COVID-19 pandemic.
DFC support will help Gavi’s efforts to pre-purchase up to 2 billion vaccines directly from manufacturers and allocate these vaccines rapidly and equitably throughout the world. DFC’s financing will offer protection against political risks in nine self-financing countries – across Latin and Central America, the Middle East, and Eastern Europe – participating in COVAX, covering a total amount of more than $383 million in insurance…

20 September 2021
Iceland renews commitment to global equitable access to vaccines: first doses arrive in Côte d’Ivoire
:: As part of a donation of 125,726 doses to COVAX, the first shipment of 35,700 doses of the AstraZeneca vaccine donated by Iceland has arrived in Côte d’Ivoire. This Icelandic commitment to global health comes on top of a pledge of ISK 750 million to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC).
:: Gudlaugur Thor Thordarson, Iceland’s Minister for Foreign Affairs and International Development Cooperation: “Iceland is firmly committed to play its part. Equitable access to vaccines is not only a fundamental matter of global solidarity but a shared interest of us all.”
:: Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance: “Iceland has long punched above its weight in development and global health: this shipment of Icelandic doses through COVAX underlines the government’s commitment to global equitable access to vaccines.”…

GHIT Fund [to 25 Sep 2021]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 212 with the aim of developing new tools to tackle infectious diseases that
No new digest content identified.

Global Fund [to 25 Sep 2021]
https://www.theglobalfund.org/en/news/
News & Stories
No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 25 Sep 2021]
https://www.glopid-r.org/news/
22/09/2021
COVID-19: Advances and Remaining Challenges international conference opens September 29
Institut Pasteur will hold this international conference in collaboration with Inserm ANRS – Maladies infectieuses émergentes from September 29 to October 1, 2021. COVID-19 experts from around the globe will attend the event which will be broadcast live in English and held under the high patronage of the French President.
Leading researchers and clinicians will present the progress made and remaining challenges in virology, clinical presentations and management, epidemiology, and vaccinology for COVID-19. Topics to be covered include:
Viral entry and replication/neutralization
Viral persistence and Long COVID
Patient management and future treatments
Evaluation of impact of interventions
Children and SARS-CoV-2 transmission and control
Vaccine regimens and effectiveness
Why and how should we get the planet vaccinated?
Learn more & register

Hilleman Laboratories [to 25 Sep 2021]
http://www.hillemanlabs.org/
Website reports “under maintenance” at inquiry

Human Vaccines Project [to 25 Sep 2021]
http://www.humanvaccinesproject.org/
News
Global COVID Lab Meeting
Sep 23, 2021
Aaron Ring: Autoantibodies in COVID-19

IAVI [to 25 Sep 2021]
https://www.iavi.org/newsroom
Latest News
No new digest content identified.

 

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

ICRC [to 25 Sep 2021]
https://www.icrc.org/en/whats-new
Selected News Releases, Statements, Reports
President Peter Maurer UNGA 2021: International Humanitarian Law – Enhancing Monitoring, Improving Compliance
Excellencies, ladies and gentlemen,This year I have visited ICRC operations in Afghanistan, the Central African Republic, Mozambique, Syria, and Yemen, among others. Unique contexts but the same equation: when wars are fought in violation of the law,
22-09-2021 | Statement

 

ICRC Statement for the 2021 Security Council Open Debate: Climate and Security
The International Committee of the Red Cross (ICRC) welcomes today’s important debate held during high level week at the initiative of the Irish Presidency and chaired by his excellency Prime Minister Micheál Martin.As an exclusively humanitarian org
22-09-2021 | Article

 

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC [to 25 Sep 2021]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
Africa CDC, IFRC, and USAU call for equitable vaccine coverage in Africa
Addis Ababa, 23 September 2021 – Today, during a high-level event on COVID-19, on the margins of the UN General Assembly, the Africa Centres for Disease Control and Prevention (Africa CDC), the International Federation of Red Cross and Red Crescent Societies (IFRC) and the U.S. Mission to the African Union (USAU) called on partners and governments to do more to end vaccine inequity. The event entitled “Saving Lives, Saving Livelihoods: Achieving high-level, equitable, COVID-19 vaccine coverage in African Union (AU) Member States” aimed to follow-up the Global COVID-19 summit convened by U.S. President Joseph R. Biden on September 22, with local African partners.

Much of the population of Africa is being left behind, even as other parts of the world begin their path to recovery from this deadly pandemic. The deep inequities in vaccine distribution are also linked to the devastating socio-economic impacts of COVID-19. According to a report released in April 2021, economic disruption is likely to persist in Africa due to COVID-19 restrictions—and the slow pace of vaccine rollouts. Worryingly, Africa has been facing multiple, chronic crises, including poverty and food insecurity, which have been exacerbated by COVID-19.

Africa CDC, IFRC and USAU warned that, in addition to slow vaccine rollouts, the presence of several crises, including COVID-19, in many African countries, is resulting in the continued loss of lives and livelihoods. The three institutions also indicated that having the vaccine doses alone won’t be enough.
John Nkengasong, Africa CDC Director, said: “As we call for the end of vaccine inequity, we know that the work doesn’t end there. We also need to be able to deliver those vaccines to the communities; ensure that people are prepared to be vaccinated and that the doses are being delivered where they are needed. It is crucial to continue working more closely with communities.”…

 

IFRC ramps up humanitarian assistance as record number of migrants cross the perilous Darién Gap
The IFRC is ramping up efforts to provide protection and humanitarian assistance to migrants travelling through the Darién Gap, one of the most dangerous migratory routes in the world.
Panama City/Geneva, 20 September 2021

Institut Pasteur [to 25 Sep 2021]
https://www.pasteur.fr/en/press-area
Press Documents
2.09.2021
SARS-CoV-2-related viruses capable of infecting human cells discovered in bats in northern Laos

IOM / International Organization for Migration [to 25 Sep 2021]
http://www.iom.int/press-room/press-releases
News – Selected
News 22 Sep 2021
Yemen: Millions of Displaced Persons and Migrants Desperate for Aid Amid Funding Shortfalls

ISC / International Science Council [to 25 Sep 2021]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
Blog
Seven organizations we want to hear more from on diversity in science
20.09.2021

IVAC [to 25 Sep 2021]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

IVI [to 25 Sep 2021]
http://www.ivi.int/
No new digest content identified.

Johns Hopkins Center for Health Security [to 25 Sep 2021]
https://www.centerforhealthsecurity.org/news/center-news/
Center News
New Report: Mental Health and Social Support for Healthcare and Hospital Workers During the COVID-19 Pandemic
September 23, 2021

MSF/Médecins Sans Frontières [to 25 Sep 2021]
http://www.msf.org/
Latest [Selected Announcements]
Democratic Republic of Congo
Deadly typhoid outbreak under control in Popokabaka
Project Update 24 Sep 2021

Ukraine
Fighting tuberculosis with medication, mental health and social support
Project Update 19 Sep 2021

National Academy of Medicine – USA [to 25 Sep 2021]
https://nam.edu/programs/
Selected News/Programs
Four NAM Members Appointed to President’s Council of Advisors on Science and Technology (PCAST)
September 23, 2021
President Joseph Biden announced the members of the President’s Council of Advisors on Science and Technology (PCAST) on September 22, 2021, including four members of the National Academy of Medicine and 20 members of the National Academy of Sciences, National Academy of Engineering, and/or NAM. The NAM members appointed to PCAST include: Lisa A. Cooper […]

More Than 150 Innovators Awarded in Global Competition Seeking Solutions with the Aim to Improve Healthy Longevity
September 22, 2021
The National Academy of Medicine (NAM), together with eight global collaborators representing over 50 countries and territories, today announced the awardees of the 2021 Healthy Longevity Catalyst Awards. These awards are part of the Healthy Longevity Global Competition, a multiyear, multistage, and multimillion-dollar international competition seeking potential breakthrough innovations aiming to extend human health and […]

National Academy of Sciences – USA [to 25 Sep 2021]
http://www.nasonline.org/news-and-multimedia/
News
No new digest content identified.

National Vaccine Program Office – U.S. HHS [to 25 Sep 2021]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

NIH [to 25 Sep 2021]
http://www.nih.gov/news-events/news-releases
News Releases
No new digest content identified.

PATH [to 25 Sep 2021]
https://www.path.org/media-center/
Press Releases
PATH signs action plan against COVID-19 at the US Global COVID-19 Summit
PATH commits to helping vaccinate 70 percent of the world by September 2022, to saving lives now, and to better preparing the world for the next health threat.
… Finally, we will hold global leaders accountable to the funding and commitments they have made to make sure we reach the goal of 70 percent of the world vaccinated by next year.

Sabin Vaccine Institute [to 25 Sep 2021]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

UNAIDS [to 25 Sep 2021]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
24 September 2021
Partnering to get back on track to end AIDS by 2030

21 September 2021
Community-led initiative helps LGBTI migrants to learn their rights in Ecuador

21 September 2021
New report outlines the impact of United Kingdom aid cut on the global HIV response

21 September 2021
Empty promises will not save the world from COVID, campaigners warn ahead of Biden Global Vaccine Summit

20 September 2021
Inequalities at the heart of uneven progress in the AIDS response

UNHCR Office of the United Nations High Commissioner for Refugees [to 25 Sep 2021]
http://www.unhcr.org/en-us/media-centre.htmlS
Selected News Releases, Announcements
UNHCR and Council of Europe discuss statelessness, urge States to uphold the right to a nationality in Europe
24 Sep 2021

 

UNHCR and IOM shocked and dismayed by deaths near Belarus-Poland border
21 Sep 2021

UNICEF [to 25 Sep 2021]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
Press release
09/24/2021
New storybook to help children stay hopeful during COVID-19
Resource for parents, teachers and health professionals follows successful first edition

Press release
09/23/2021
Global leaders commit further support for global equitable access to COVID-19 vaccines and COVAX
A joint statement from COVAX partners
[See Milestones above for detail]

Press release
09/23/2021
Over 2 in 3 people expelled to Haiti from US border are women and children – UNICEF
UNICEF also concerned about situation of Haitian families at US-Mexico border

Remarks
09/21/2021
UNICEF Executive Director remarks at the virtual Ministerial-Event on safeguarding the achievements of 20 years of international engagement in Afghanistan
Checked against delivery

Press release
09/21/2021
Young children’s diets show no improvement in last decade, ‘could get much worse’ under COVID-19
During crucial period when children begin to transition to solid foods, just 1 in 3 are fed a diet diverse enough to grow well

Unitaid [to 25 Sep 2021]
https://unitaid.org/
Featured News
24 September 2021
Unitaid’s statement on the recommendation of casirivimab/imdevimab for COVID-19 treatment
Geneva, 24 September 2021 – Unitaid welcomes the WHO guidelines published today that recommend the use of the combination of two monoclonal antibodies for the treatment for both outpatients and patients hospitalized with COVID-19.
The need to have effective treatments for COVID-19 has never been greater, with many countries around the world facing case surges driven by Delta and other variants. These surges are having a particularly devastating impact on low- and middle- income countries, which continue to have limited access to vaccines.
Global, equitable access to new tools against COVID-19 is crucial if we are to ensure that hard-won developments in the fight against the pandemic can reach all those who may benefit. We now need to see how new therapeutic options, as they become recommended, can reach their potential in all settings, including in low- and middle-income countries.
With this newly recommended treatment, Unitaid notes the feasibility challenges, severely constrained supply, and – for non-hospitalized patients – limited benefit for all but those at highest risk, as detailed in the guidelines. WHO allocation criteria will be critical in helping identify people who may benefit from this treatment. A proposed initial donation from Roche/Regeneron, to be managed by UNICEF, could help meet immediate needs and ensure casirivimab/imdevimab reaches people who could benefit. However a limited donation – on its own – is not enough to ensure equitable, global access to lifesaving COVID-19 treatments. Broader access commitments are needed from industry to ensure that pricing and supply conditions enable this product to reach all people regardless of where they live…

Vaccine Equity Cooperative [nee Initiative] [to 25 Sep 2021]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin) [to 25 Sep 2021]
https://www.vaccineacceptance.org/
Announcements
No new digest content identified.

Vaccine Confidence Project [to 25 Sep 2021]
http://www.vaccineconfidence.org/
News, Research and Reports
Coronavirus global impact
Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

Goals House @UNGA | HOW COVID-19 IS CHANGING THE WAY THE WORLD THINKS ABOUT VACCINES
Prof. Heidi Larson participated in the UK Government-hosted virtual roundtable “How COVID-19 is changing the way the world thinks about vaccines: lessons for the future of global health” as part of the Global Goals House series of events that coincide with United Nations General Assembly Week. The debate explored the evolution of public sentiment around vaccines from before the pandemic to present day and identified the most effective approaches adopted – from enhanced public perception and misinformation tracking to rapid message deployment – to build confidence in vaccines and promote uptake.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 25 Sep 2021]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

Wellcome Trust [to 25 Sep 2021]
https://wellcome.ac.uk/news
News and reports
News
Learning from pandemics
Head of Prevention, Charlie Weller spoke to us about how the lessons of previous epidemics helped us respond to Covid-19.
21 September 2021

The Wistar Institute [to 25 Sep 2021]
https://www.wistar.org/news/press-releases
Press Releases
Sep. 22, 2021
Wistar and Penn Medicine Awarded $11.7 Million Melanoma Research Grant from the National Cancer Institute
PHILADELPHIA — (Sept. 22, 2021) —The Wistar Institute and Penn Medicine have been awarded a prestigious $11.7 million Specialized Programs of Research Excellence, or SPORE, grant from the National Cancer Institute. The five-year award will fund three new melanoma research projects that translate fundamental laboratory discoveries made at The Wistar Institute and in the Perelman School of Medicine at the University of Pennsylvania into new therapeutics to treat skins cancers.

WFPHA: World Federation of Public Health Associations [to 25 Sep 2021]
https://www.wfpha.org/
Latest News
Eradicating Polio: What more Is Needed?
Sep 22, 2021
Polio cases have fallen 99.9% since 1988. In 2020 Africa was certified polio free by the World Health Organization. However, polio will remain a key public health concern until such time as there are no wild… On October 12, 2021, at 10:00 – 11:00 (CEST), “Eradicating Polio: What more Is Needed?” webinar will be held to focus on the barriers, challenges and leverages to reach every child and eradicate polio globally. Register

World Bank [to 25 Sep 2021]
http://www.worldbank.org/en/news/all
Selected News, Announcements
Remarks by World Bank Group President David Malpass for UNGA21 Global COVID-19 Summit
Date: September 22, 2021 Type: Speeches and Transcripts
President Biden, excellencies, and distinguished colleagues.
The World Bank Group is strongly supporting widespread access to COVID-19 vaccines, particularly in developing countries. We welcome the global target of having at least 70 percent of the population fully vaccinated in all countries by UNGA 2022.

To help support this, the World Bank Group has a $20 billion facility to help developing countries purchase vaccines and set up vaccination systems. We have funded vaccination programs in 54 countries.  We are eager to increase both the amounts of funding and the range of countries, including through COVAX.

We have partnered with the African Union’s African Vaccine Acquisition Trust – AVAT – to increase delivery of vaccine doses for African and Caribbean countries and to tackle persistent vaccine delivery, manufacturing, and trade issues.

Shortages of vaccine deliveries remain a critical bottleneck.  The World Bank Group, with the IMF, WHO, and WTO have formed a Task Force to accelerate access to COVID-19 vaccines. The Multilateral Task Force’s data and analysis show that advanced economies have billions of excess doses beyond what is required to vaccinate their entire populations.

We’re urging countries with excess vaccine supplies to release doses quickly and transparently and to fulfill their generous donation pledges.

The Task Force is also urging governments to eliminate trade and regulatory barriers to the export of vaccines and other COVID-19 health tools. To help build supply, the IFC, which is the World Bank Group’s private sector development arm, is investing in vaccine manufacturing and working to boost local production capacity in Africa.

Stopping the spread of COVID-19 through widespread vaccine distribution will increase health security for everyone and is critical to a full return to inclusive growth everywhere.
Thank you.

World Customs Organization – WCO [to 25 Sep 2021]
http://www.wcoomd.org/
Latest News – Selected Items
24 September 2021
Gender equality and inclusion in Customs at the forefront of high-level discussions

World Organisation for Animal Health (OIE) [to 25 Sep 2021]
https://www.oie.int/en/for-the-media/press-releases/2021/
Press Releases, Statements
No new digest content identified.

WTO – World Trade Organisation [to 25 Sep 2021]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events
DG Okonjo-Iweala: Leverage trade to build sustainable food systems
23 September 2021
In a video message to the United Nations’ Food Systems Summit on 23 September, Director-General Ngozi Okonjo-Iweala underscored the importance of international trade in building sustainable food systems. Noting the opportunity provided by the 12th Ministerial Conference in late November to make progress on critical agricultural issues, she called on world leaders to support and reinvigorate the trading system to ensure greater sustainability.
News item

Access to COVID-19 vaccine, ministerial outcomes key to driving development in LLDCs
23 September 2021
Deputy Director-General Xiangchen Zhang called on the global community to increase the access of landlocked developing countries (LLDCs) to the COVID-19 vaccine and to achieve outcomes at the WTO’s 12th Ministerial Conference that will support sustainable development. DDG Zhang was speaking at the LLDC ministerial meeting held virtually on the margins of the UN General Assembly on 23 September. “The decisions and agreements reached at the WTO will determine the future of the multilateral trading system and its potential to keep driving development,” he said.
[Excerpt]

…Countries’ economic prospects are bifurcating in line with their access to vaccines and their fiscal and monetary capacity to provide economic relief and stimulus. LLDCs are in a weaker position with regard to access to the vaccine and the financial capacity to adopt stimulus measures. The multilateral community needs to step forward to make up for these shortcomings.
A rapid, equitable vaccine rollout is a prerequisite for inclusive economic growth and continuing progress towards the achievement of the objectives of the 2030 Sustainable Development Agenda and the Vienna Program of Action.
The WTO, together with our partners WHO, the IMF and the World Bank, has been working with vaccine manufacturers to enhance production, including new investments in emerging markets and developing countries and ensure equitable access to vaccines for all. Our joint task force has a website with vaccine data and news — COVID19taskforce.com.
The response to the pandemic will be a central issue during our conversations at the WTO’s 12th Ministerial Conference in just over two-months time. To achieve meaningful results that will make a difference in responding to this and any future pandemics, we are focusing on three key areas:
One, free up vaccine supply chains by lowering export restrictions and facilitating trade.
Two, work with manufacturers to identify supply chain bottlenecks and increase production in developing countries.
And three, find pragmatic solutions to technology transfer, knowhow, and intellectual property questions…
News item

 

DG Okonjo-Iweala: Vaccine policy key to sustainable economic and trade recovery
23 September 2021
Speaking at the virtual White House Global COVID-19 Summit on 22 September, Director-General Ngozi Okonjo-Iweala said sustainable economic and trade recovery can only be achieved with a policy that ensures rapid global access to vaccines.
[Excerpt]
…Vaccinating the world is a moral, practical, and economic imperative.

Moral, because we cannot accept that in a world where the technology exists to save lives, we let people die because they live in poor countries that have neither the resources, nor the access to vaccines and other medical countermeasures needed to save their populations. It is not acceptable that 58% of people in developed countries are fully vaccinated, with vaccines available to anybody who wants one, while in low-income countries, barely 1% of people are vaccinated, and even frontline medical workers are denied access for want of supply.

Practical, because the longer the virus circulates freely, the likelier it is that variants even more dangerous than Delta will emerge and go global.

And economic, because the present K-shaped economic recovery is not sustainable. Currently, economies with abundant vaccines and ample fiscal and monetary firepower — which is to say, mostly rich countries and some Emerging Markets — have rebounded strongly. But other countries are being left behind. Extreme poverty is rising after decades of decline. According to the IMF, advanced economies will grow 5.6% this year, compared to only 3.9% for low-income developing countries. WTO projections show a similar trend in trade: Asia, North America, and Europe are on track for stronger trade growth than Africa and Latin America.

 

We have a choice. Either we converge downwards, by allowing the virus to drag us all back down, or we converge upwards, by vaccinating the world…

::::::

ARM [Alliance for Regenerative Medicine] [to 25 Sep 2021]
https://alliancerm.org/press-releases/
Selected Press Releases
No new digest content identified.

BIO [to 25 Sep 2021]
https://www.bio.org/press-releases
Press Releases, Letters, Testimony, Comments [Selected]
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 25 Sep 2021]
http://www.dcvmn.org/
News; Upcoming events
BioManguinhos and Sinergium Biotech selected by PAHO to develop COVID-19 mRNA vaccines
Washington DC, September 21, 2021 (PAHO) – The Pan American Health Organization (PAHO) has announced the selection of Sinergium Biotech, in Argentina and Bio-Manguinhos, in Brazil, as regional hubs for the development and production of mRNA-based vaccines in Latin America in a bid to tackle COVID-19 and future infectious-disease challenges.

The Bio-Manguinhos Institute of Technology on Immunobiologicals at the Oswaldo Cruz Foundation (FIOCRUZ) has a long tradition in vaccine manufacturing and has made promising advances in the development of an innovative mRNA vaccine against COVID-19. Sinergium Biotech, a private sector biopharmaceutical company, will partner with pharmaceutical mAbxience, to develop and manufacture active vaccine ingredients. The two companies have extensive experience in the production and development of vaccines and biotechnological medicines.

The announcement was made by PAHO Assistant Director Dr Jarbas Barbosa and Dr. Soumya Swaminathan, World Health Organization (WHO) Chief Scientist, during a side event on the margins of PAHO’s 59th Directing Council. The “Technology Transfer for the Production of mRNA Vaccines in the Americas” event brought together health ministers and authorities from countries in the region to discuss vaccine production. “Delays in production have meant that many countries [in the region] are still awaiting the doses they purchased months ago. Limited vaccine supplies continue to set us back,” PAHO Director Dr. Carissa F. Etienne said in her opening remarks to the side event.

The region of the Americas has borne the brunt of COVID-19 infections to date, with 87.6 million cases recorded and over 2.16 million lives lost. Vaccine distribution continues to be unequal, with few countries in the region reaching the 40% COVID-19 vaccine target set out by WHO.

ICBA – International Council of Biotechnology Associations [to 25 Sep 2021]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA [to 25 Sep 2021]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
IFPMA EFPIA PhRMA BIO ABPI Statement – Global COVID-19 Summit: Ending the Pandemic and Building
22 September 2021
Innovative biopharmaceutical companies are at the forefront of the response to the pandemic; not least by developing and manufacturing COVID-19 vaccines in record time. Our industry joins today’s global summit to demonstrate our commitment towards working with governments and global health partners to align on a common vision to expand and enhance our shared efforts to defeat COVID-19.

This month COVID-19 vaccine manufacturing output will reach 7.5 billion doses, and 12 billion vaccines will be produced by the end of 2021. At this rate, on the basis of the most conservative projections (Airfinity report), even if governments in G7 countries decide to vaccinate teenagers and adults at a rate of more than 80% and decide to give boosters to at-risk populations, there would still be over 1.2 billion doses available for distribution by the end of this year. By June 2022, if there are no major bottlenecks and trade barriers, output will reach over 24 billion.

We are fully committed to “vaccinate the world” as articulated in our “Five steps to urgently advance COVID-19 vaccine equity” we are working with governments and partners to:
step up dose sharing,
continueefforts to optimize production,
eliminatetrade barriers,
support country readiness, and
continue to drive innovation.

The G7 and G20 countries are making strides to increase dose sharing and we welcome the increased focus from these leaders to respond to the challenge of greater dose sharing.  Now, in addition to doses already committed, each month, over 200 million doses secured by G7 countries could be available for low- and lower-middle-income countries. Political leadership is critical to distributing the 1.2 billion doses by the end of 2021; and developing robust plans to enable the efficient distribution of these doses with due regard to the capacity in low- and lower-income countries to roll out immunization plans across their priority populations and achieve vaccine equity.

To “save lives now”, treatments remain integral to COVID-19 mitigation strategies. Thankfully, a handful of COVID-19 treatments are already standard of care. The biopharmaceutical industry is continuing to research, develop and scale up manufacturing capacity for existing and novel treatments, but their effective roll out to patients is dependent on country readiness to ensure the right patient gets the right treatment at the right time.

Strengthening health systems to ensure that COVID-19 vaccines and treatments get to all who need them will be the foundation for “building back better” and ensuring all patients will benefit from future innovation. To stave off future pandemics, society needs a thriving innovation eco-system alongside a resilient, sufficiently resourced, health infrastructure that will sustain the development, production and deployment of vaccines and therapeutics vital to continued global health progress.

 

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

International Alliance of Patients’ Organizations – IAPO [to 25 Sep 2021]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

PhRMA [to 25 Sep 2021]
http://www.phrma.org/
Latest News [Selected]
A global focus on ending the COVID-19 pandemic
September 22, 2021
Stephen J. Ubl is president and chief executive officer of PhRMA.
Today, President Biden convened global leaders to confront the challenges around ending this pandemic. We stand with the president, all governments, organizations and sectors in a shared commitment to:
Vaccinate the world; Save lives now; and Be better prepared for the next public health crisis.
Since the onset of the COVID-19 pandemic, America’s biopharmaceutical companies have come together in unprecedented ways to attack the virus. These include enhancing testing availability, working closely with hospitals and physicians on thousands of clinical trials, and teaming up with competitors and new partners through hundreds of collaborations in countries around the world to manufacture and deliver vaccines.
Biopharmaceutical companies have ramped up COVID-19 vaccine production from zero to as many as 12 billion doses this year. We are also working to address barriers standing in the way of global vaccination, including vaccine hesitancy and further increasing production and partnerships. As I’ve said previously, waiving commitments to protect vaccine intellectual property would threaten our collective ability to meet the ambitious global vaccination goals by compromising efforts to expand global manufacturing capacity and jeopardize safety.
Plus, our companies continue to innovate as the virus evolves, with ongoing research into new and existing treatments and vaccines. Today, there are more than 600 global unique therapies for COVID-19 in trial, including several that have already made their way to patients. Furthermore, COVID-19 has demonstrated that we need a more resilient health care system that works for all patients and robust support for innovation. For instance, we were prepared to fight COVID-19 due to years of industry investments in technology, like mRNA. We need to make these same smart investments today to prepare for tomorrow’s world.
Our industry will continue to drive coordination, collaboration and joint problem-solving across the research and development, manufacturing and distribution ecosystems to fight the pandemic. Our work is not done. I was honored to participate in this international gathering focused on solutions that will end this pandemic and get our world back to normal. The biopharmaceutical industry is committed to being a partner with all stakeholders to beat COVID-19.
Blog Post

PhRMA awards $150,000 to community-based projects aimed at tackling inequities in access to COVID-19 testing, vaccines and therapeutics
September 21, 2021
Today, we are thrilled to announce the PhRMA CAREs grant program has awarded $150,000 to fund four additional initiatives aimed at reducing inequities.
Blog Post

PhRMA releases 2021 industry profile
September 20, 2021
Today, PhRMA released its 2021 Biopharmaceutical Industry Profile, a resource that highlights the latest from the industry on innovation, access, and affordability.
Blog Post

Journal Watch

Posted on by

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Deliberation on Childhood Vaccination in Canada: Public Input on Ethical Trade-Offs in Vaccination Policy

Posted on by

AJOB Empirical Bioethics
Volume 12, 2020 Issue 3
https://www.tandfonline.com/toc/uabr21/current

 

Research Article
Deliberation on Childhood Vaccination in Canada: Public Input on Ethical Trade-Offs in Vaccination Policy
Kieran C. O’Doherty, Sara Crann, Lucie Marisa Bucci, Michael M. Burgess, Apurv Chauhan, Maya J. Goldenberg, show all
Published online: 30 Jul 2021
Abstract
Background
Policy decisions about childhood vaccination require consideration of multiple, sometimes conflicting, public health and ethical imperatives. Examples of these decisions are whether vaccination should be mandatory and, if so, whether to allow for non-medical exemptions. In this article we argue that these policy decisions go beyond typical public health mandates and therefore require democratic input.
Methods
We report on the design, implementation, and results of a deliberative public forum convened over four days in Ontario, Canada, on the topic of childhood vaccination.
Results
25 participants completed all four days of deliberation and collectively developed 20 policy recommendations on issues relating to mandatory vaccinations and exemptions, communication about vaccines and vaccination, and AEFI (adverse events following immunization) compensation and reporting. Notable recommendations include unanimous support for mandatory childhood vaccination in Ontario, the need for broad educational communication about vaccination, and the development of a no-fault compensation scheme for AEFIs. There was persistent disagreement among deliberants about the form of exemptions from vaccination (conscience, religious beliefs) that should be permissible, as well as appropriate consequences if parents do not vaccinate their children.
Conclusions
We conclude that conducting deliberative democratic processes on topics that are polarizing and controversial is viable and should be further developed and implemented to support democratically legitimate and trustworthy policy about childhood vaccination.

Still in the Dark Regarding the Public Health Impact of COVID-19 on Sexual and Gender Minorities

Posted on by

American Journal of Public Health
September 2021 111(9)
http://ajph.aphapublications.org/toc/ajph/current

 

EDITORIALS
Still in the Dark Regarding the Public Health Impact of COVID-19 on Sexual and Gender Minorities
Government, Other Statistics/Evaluation/Research, Statistics/Evaluation/Research, Lesbian/Gay/Bisexual/Transgender Persons, Health Policy
Sean R. Cahill

Best Practices for Conducting Clinical Trials With Indigenous Children in the United States

Posted on by

American Journal of Public Health
September 2021 111(9)
http://ajph.aphapublications.org/toc/ajph/current

 

ETHICS
Best Practices for Conducting Clinical Trials With Indigenous Children in the United States
Jennifer L. Shaw, Erin Semmens, May Okihiro, Johnnye L. Lewis, Matthew Hirschfeld, Timothy M. VanWagoner, Lancer Stephens, David Easa, Judith L. Ross, Niki Graham, Sara E. Watson, Edgardo G. Szyld, Denise A. Dillard, Lee A. Pyles, Paul M. Darden, John C. Carlson, Paul G. Smith, Russell J. McCulloh, Jessica N. Snowden, Sarah H. Adeky and Rosalyn Singleton

Mandating COVID-19 Vaccination for Health Care Workers

Posted on by

Annals of Internal Medicine
September 2021 Volume 174, Issue 9
http://annals.org/aim/issue

Mandating COVID-19 Vaccination for Health Care Workers
FREE

 

Ezekiel J. Emanuel, MD, PhD, David J. Skorton, MD
Pages:1308–1310
…It is imperative that all 17 million health care workers in the United States be vaccinated (5). The best way to achieve this is for them to choose vaccination. However, in the current situation, health care employers should mandate vaccination…

Household expenditure for immunization among children in India: a two-part model approach

Posted on by

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 25 Sep 2021)

 

Household expenditure for immunization among children in India: a two-part model approach
Despite the Indian government’s Universal Immunization Program (UIP), the progress of full immunization coverage is plodding. The cost of delivering routine immunization varies widely across facilities within …
Authors: Shobhit Srivastava, Pradeep Kumar, Shekhar Chauhan and Adrita Banerjee
Citation: BMC Health Services Research 2021 21:1001
Content type: Research
Published on: 22 September 2021

Ethical considerations for involving adolescents in biomedical HIV prevention research

Posted on by

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 25 Sep 2021)

 

Ethical considerations for involving adolescents in biomedical HIV prevention research
Involvement of adolescent girls in biomedical HIV research is essential to better understand efficacy and safety of new prevention interventions in this key population at high risk of HIV infection. However, t…
Authors: Rita Nakalega, Carolyne Akello, Brenda Gati, Clemensia Nakabiito, Monica Nolan, Betty Kamira, Juliane Etima, Teopista Nakyanzi, Doreen Kemigisha, Sophie C. Nanziri, Stella Nanyonga, Maria Janine Nambusi, Emmie Mulumba, Florence Biira, Hadijah Kalule Nabunya, Simon Afrika Akasiima…
Citation: BMC Medical Ethics 2021 22:127
Content type: Research
Published on: 23 September 2021

Influenza vaccine uptake among at-risk adults (aged 16–64 years) in the UK: a retrospective database analysis

Posted on by

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 25 Sep 2021)

 

Influenza vaccine uptake among at-risk adults (aged 16–64 years) in the UK: a retrospective database analysis
In the UK, annual influenza vaccination is currently recommended for adults aged 16–64 years who are in a clinical at-risk group. Despite recommendations, rates of vaccine uptake in the UK have historically be…
Authors: Simon Oakley, Julien Bouchet, Paul Costello and James Parker
Citation: BMC Public Health 2021 21:1734
Content type: Research
Published on: 24 September 2021

Evaluation of the impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia in Ulaanbaatar, Mongolia: study protocol for an observational study

Posted on by

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 25 Sep 2021)

 

Evaluation of the impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia in Ulaanbaatar, Mongolia: study protocol for an observational study
Community-acquired pneumonia is an important cause of morbidity and mortality in adults. Approximately one-third of pneumonia cases can be attributed to the pneumococcus. Pneumococcal conjugate vaccines (PCVs)…
Authors: Claire von Mollendorf, Mukhchuluun Ulziibayar, Bradford D. Gessner, Lien Anh Ha Do, Cattram D. Nguyen, Rohini Beavon, Bujinlkham Suuri, Dashtseren Luvsantseren, Dorj Narangerel, Adam Jenney, Eileen M. Dunne, Catherine Satzke, Badarchiin Darmaa, Tuya Mungun and E. Kim Mulholland
Citation: BMC Public Health 2021 21:1731
Content type: Study protocol
Published on: 23 September 2021

Childhood immunisation timeliness and vaccine confidence by health information source, maternal, socioeconomic, and geographic characteristics in Albania

Posted on by

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 25 Sep 2021)

 

Childhood immunisation timeliness and vaccine confidence by health information source, maternal, socioeconomic, and geographic characteristics in Albania
Albania is facing decreasing childhood immunisation coverage and delay in timeliness of vaccination despite a growing economy and universal health insurance. Our aim is to estimate childhood immunisation timel…
Authors: Daniela Mayerová and Kaja Abbas
Citation: BMC Public Health 2021 21:1724
Content type: Research
Published on: 22 September 2021

Strengthening the evidence base for decisions on public health and social measures

Posted on by

Bulletin of the World Health Organization
Volume 99(9);  2021 Sep 1
https://www.ncbi.nlm.nih.gov/pmc/issues/388476/

 

Editorials
Strengthening the evidence base for decisions on public health and social measures
Delia Enria, Zijian Feng,, Atle Fretheim, Chikwe Ihekweazu, Trygve Ottersen, Anne Schuchat, Kumnuan Ungchusak,, Sylvie Briand, Victoria Haldane, Jaya Lamichhane, Ramona Ludolph, Margaux Mathis, Tim Nguyen, Nahoko Shindo
Bull World Health Organ. 2021 Sep 1; 99(9): 610–610A. Published online 2021 Sep 1. doi: 10.2471/BLT.21.287054
PMCID: PMC8381089

Vaccination for SARS-CoV-2 of migrants and refugees, Jordan

Posted on by

Bulletin of the World Health Organization
Volume 99(9);  2021 Sep 1
https://www.ncbi.nlm.nih.gov/pmc/issues/388476/

 

Vaccination for SARS-CoV-2 of migrants and refugees, Jordan
Saverio Bellizzi, Chinara Aidyralieva, Lora Alsawhala, Ala’a Al-Shaikh, Alessio Santoro, Maria Cristina Profili
Bull World Health Organ. 2021 Sep 1; 99(9): 611. Published online 2021 Sep 1. doi: 10.2471/BLT.21.285591
PMCID: PMC8381092

Subnational inequalities in diphtheria–tetanus–pertussis immunization in 24 countries in the African Region

Posted on by

Bulletin of the World Health Organization
Volume 99(9);  2021 Sep 1
https://www.ncbi.nlm.nih.gov/pmc/issues/388476/

 

Research
Subnational inequalities in diphtheria–tetanus–pertussis immunization in 24 countries in the African Region
Katherine Kirkby, Nicole Bergen, Anne Schlotheuber, Samir V Sodha, M Carolina Danovaro-Holliday, Ahmad Reza Hosseinpoor
Bull World Health Organ. 2021 Sep 1; 99(9): 627–639. Published online 2021 Jul 1. doi: 10.2471/BLT.20.279232
PMCID: PMC8381099

Improvements to a framework for gender and emerging infectious diseases

Posted on by

Bulletin of the World Health Organization
Volume 99(9);  2021 Sep 1
https://www.ncbi.nlm.nih.gov/pmc/issues/388476/

 

Perspectives
Improvements to a framework for gender and emerging infectious diseases
Lynn Lieberman Lawry, Roberta Lugo-Robles, Vicki McIver
Bull World Health Organ. 2021 Sep 1; 99(9): 682–684. Published online 2021 Jul 2. doi: 10.2471/BLT.20.275636
PMCID:
PMC8381096

Supplement: E-Mental-Health: Exploring the Evidence Base and Stakeholders’ Perspectives on Internet-Based Interventions for the Prevention of Mental Health Conditions

Posted on by

The European Journal of Public Health
SUPPLEMENT – Volume 31, Issue Supplement_1, July 2021
https://academic.oup.com/eurpub/issue/31/Supplement_1

 

Supplement: E-Mental-Health: Exploring the Evidence Base and Stakeholders’ Perspectives on Internet-Based Interventions for the Prevention of Mental Health Conditions
Mental illness represents an enormous personal, social and societal burden for European citizens1 calling for the need to expand existing models of mental healthcare delivery. In Europe, the Internet is a key source of health information,2 and technology-enhanced (psychological) interventions such as Internet- and mobile-delivered applications (‘eHealth’3 and ‘m-Health’4) have become increasingly popular and studied. There is already strong evidence of the efficacy of online interventions for the prevention and treatment of several psychological disorders5,6 and meta-analyses show effect sizes similar to face-to-face interventions.7

Rejoice architecture meets social norms to accelerate vaccination in Nepal: Protocol for a mixed-method quasi-experimental study

Posted on by

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 25 Sep 2021]

 

Study Protocol metrics
Revised
Rejoice architecture meets social norms to accelerate vaccination in Nepal: Protocol for a mixed-method quasi-experimental study [version 2; peer review: 1 approved, 2 approved with reservations]
Alicia Paul, Kamana Upreti, Shraddha Nepal, Jeevan Lohani, Kriti Adhikari, Rajiv Rimal
Peer Reviewers Ann M. Weber; Nimesh Poudyal and Ondari D. Mogeni; Robert A. Bednarczyk
Funder – Bill and Melinda Gates Foundation
LATEST VERSION PUBLISHED 22 Sep 2021
Abstract
Background: Each year, 600,000 children under 5 years old die from vaccine-preventable diseases globally. Immunization is an effective way to prevent many diseases, saving two to three million lives per year. The Nepal National Government recommends vaccinations for all children for 11 diseases by 15 months of age. However, only 78% of children between 1-2 years of age have received all recommended vaccines and only 43% receive them at the age-appropriate times for which they are scheduled.
Objectives: This protocol describes the development of an intervention – called “Rejoice Architecture” – that is informed by three theoretical perspectives: choice architecture, the broken windows theory, and the theory of normative social behavior. We also describe a mixed-methods approach to develop the intervention, which will improve the physical and social environments of health facilities in Makwanpur, Nepal. We hypothesize this intervention will improve immunization behaviors and intentions among mothers of children younger than 2 years, pregnant women, and prospective mothers.
Methods: We describe the qualitative formative assessment to understand existing attitudes, norms, and behaviors among caregivers, healthcare workers, and government representatives. The formative assessment will include in-depth interviews, key informant interviews, and focus group discussions. We also describe the overall quasi-experimental study design, used to assess intervention impact.
Impact: This study will contribute to the social and behavioral change communication intervention research by offering a novel strategy for increasing immunization. This study will also illustrate to policymakers the value of structural change for health service delivery.

Substandard and falsified medical products: bibliometric analysis and mapping of scientific research

Posted on by

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 25 Sep 2021]

 

Substandard and falsified medical products: bibliometric analysis and mapping of scientific research
Substandard and falsified (SF) medical products are a global public health threat. The presence and spread of SF drugs negatively affect (1) patients’ safety and health outcomes, (2) national economy, (3) publ…
Authors: Waleed M. Sweileh
Citation: Globalization and Health 2021 17:114
Content type: Research
Published on: 23 September 2021

Risky business: COVAX and the financialization of global vaccine equity

Posted on by

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 25 Sep 2021]

 

Risky business: COVAX and the financialization of global vaccine equity
During the first year and a half of the COVID-19 pandemic, COVAX has been the world’s most prominent effort to ensure equitable access to SARS-CoV-2 vaccines. Launched as part of the Access to COVID-19 Tools A…
Authors: Felix Stein
Citation: Globalization and Health 2021 17:112
Content type: Research
Published on: 20 September 2021

Interrogating the World Bank’s role in global health knowledge production, governance, and finance

Posted on by

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 25 Sep 2021]

 

Interrogating the World Bank’s role in global health knowledge production, governance, and finance
In the nearly half century since it began lending for population projects, the World Bank has become one of the largest financiers of global health projects and programs, a powerful voice in shaping health age…
Authors: Marlee Tichenor, Janelle Winters, Katerini T. Storeng, Jesse Bump, Jean-Paul Gaudillière, Martin Gorsky, Mark Hellowell, Patrick Kadama, Katherine Kenny, Yusra Ribhi Shawar, Francisco Songane, Alexis Walker, Ryan Whitacre, Sumegha Asthana, Genevie Fernandes, Felix Stein…
Citation: Globalization and Health 2021 17:110
Content type: Review
Published on: 19 September 2021

Localisation and local humanitarian action

Posted on by

Humanitarian Exchange Magazine
Number 79, May 2021
https://odihpn.org/magazine/localisation-and-local-humanitarian-action/

 

Localisation and local humanitarian action
by HPN October 2020
The theme of this edition of Humanitarian Exchange is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies,  non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported.  Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

Posted on by

JAMA
September 21, 2021, Vol 326, No. 11, Pages 993-1116
https://jamanetwork.com/journals/jama/currentissue

 

Research Letter
Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses
Ilies Benotmane, MD; Gabriela Gautier, MD; Peggy Perrin, MD; et al.
free access has active quiz
JAMA. 2021;326(11):1063-1065. doi:10.1001/jama.2021.12339
This study examines the antibody responses to a third dose (100 μg) of the mRNA-1273 SARS-CoV-2 vaccine among kidney transplant recipients in France who had not responded to 2 doses of the vaccine.

Confronting the Delta Variant of SARS-CoV-2, Summer 2021

Posted on by

JAMA
September 21, 2021, Vol 326, No. 11, Pages 993-1116
https://jamanetwork.com/journals/jama/currentissue

 

Viewpoint
Confronting the Delta Variant of SARS-CoV-2, Summer 2021
Carlos del Rio, MD; Preeti N. Malani, MD, MSJ; Saad B. Omer, MBBS, PhD
free access has active quiz has multimedia
JAMA. 2021;326(11):1001-1002. doi:10.1001/jama.2021.14811
This Viewpoint discusses the Delta variant of SARS-CoV-2, including its epidemiology, transmissibility, how uneven vaccination coverage in the US encouraged its spread, and the most effective public health responses to curb it.

Potential Implications of SARS-CoV-2 Delta Variant Surges for Rural Areas and Hospitals

Posted on by

JAMA
September 21, 2021, Vol 326, No. 11, Pages 993-1116
https://jamanetwork.com/journals/jama/currentissue

 

Potential Implications of SARS-CoV-2 Delta Variant Surges for Rural Areas and Hospitals
Sameer S. Kadri, MD, MS; Steven Q. Simpson, MD
free access has multimedia
JAMA. 2021;326(11):1003-1004. doi:10.1001/jama.2021.13941
This Viewpoint discusses the Delta variant of SARS-CoV-2 and suggests potential solutions for institutions, governments, and society as they navigate the potentially rural-dominant surge in infections.

Navigating Ethical Issues in Photovoice: Balancing the Principles of Community-Based Participatory Research Ethics with Institutional Review Board Requirements

Posted on by

Journal of Empirical Research on Human Research Ethics
Volume 16 Issue 4, October 2021
http://journals.sagepub.com/toc/jre/current

 

Navigating Ethical Issues in Photovoice: Balancing the Principles of Community-Based Participatory Research Ethics with Institutional Review Board Requirements
Lauren E. McDonald, Moshoula Capous-Desyllas
First Published July 13, 2021; pp. 364–373

A New Era of Indigenous Research: Community-based Indigenous Research Ethics Protocols in Canada

Posted on by

Journal of Empirical Research on Human Research Ethics
Volume 16 Issue 4, October 2021
http://journals.sagepub.com/toc/jre/current

A New Era of Indigenous Research: Community-based Indigenous Research Ethics Protocols in Canada
Ashley Hayward, Erynne Sjoblom, Stephanie Sinclair, Jaime Cidro

 

First Published June 9, 2021; pp. 403–417

Cultural Values and Beliefs of Selected Local Communities in Botswana: Implications for Human Subject Research Ethics Practice

Posted on by

Journal of Empirical Research on Human Research Ethics
Volume 16 Issue 4, October 2021
http://journals.sagepub.com/toc/jre/current

Cultural Values and Beliefs of Selected Local Communities in Botswana: Implications for Human Subject Research Ethics Practice
Setlhomo Koloi-Keaikitse, Gail Geller, Dudu Jankie, Joseph Ali

 

First Published June 7, 2021; pp. 424–434

Cost-effectiveness of extending the HPV vaccination to boys: a systematic review

Posted on by

Journal of Epidemiology & Community Health
September 2021 – Volume 75 – 9
https://jech.bmj.com/content/75/9

 

Review
Cost-effectiveness of extending the HPV vaccination to boys: a systematic review (23 June, 2021)
Renata Linertová, Carmen Guirado-Fuentes, Javier Mar Medina, Iñaki Imaz-Iglesia, Leticia Rodríguez-Rodríguez, Montserrat Carmona-Rodríguez

Exploring determinants of community pharmacist-led influenza vaccination in a Middle Eastern country: a national web-based cross-sectional study

Posted on by

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 25 Sep 2021]

 

Exploring determinants of community pharmacist-led influenza vaccination in a Middle Eastern country: a national web-based cross-sectional study
Authors: Dalal Youssef, Linda Abou-Abbas and Hamad Hassan
Content type: Research
20 September 2021

Artificial Intelligence and Liability in Medicine: Balancing Safety and Innovation

Posted on by

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy

 

Volume 99, Issue 3 Pages: 601-852 September 2021
https://onlinelibrary.wiley.com/toc/14680009/current
Perspectives
Artificial Intelligence and Liability in Medicine: Balancing Safety and Innovation
GEORGE MALIHA, SARA GERKE, I. GLENN COHEN, RAVI B. PARIKH
Pages: 629-647
First Published: 06 April 2021